Brian Middleton

2.6k total citations · 1 hit paper
29 papers, 2.0k citations indexed

About

Brian Middleton is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Brian Middleton has authored 29 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 9 papers in Oncology and 4 papers in Pharmacology. Recurrent topics in Brian Middleton's work include Drug Transport and Resistance Mechanisms (5 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Peptidase Inhibition and Analysis (3 papers). Brian Middleton is often cited by papers focused on Drug Transport and Resistance Mechanisms (5 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Peptidase Inhibition and Analysis (3 papers). Brian Middleton collaborates with scholars based in United Kingdom, Sweden and United States. Brian Middleton's co-authors include Matt Davison, Robert Tonge, Rachel Rowlinson, J. Young, François Pognan, Edward Hawkins, Joanne Shaw, Margareta Hammarlund‐Udenaes, Ulf Bredberg and Markus Fridén and has published in prestigious journals such as Blood, PLoS ONE and Magnetic Resonance in Medicine.

In The Last Decade

Brian Middleton

28 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology

2001 706 citations Robert Tonge, Joanne Shaw et al. PROTEOMICS profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Brian Middleton United Kingdom	16	780	409	292	287	202	29	2.0k
Jun‐ichi Nishikawa Japan	34	2.5k 3.3×	74 0.2×	93 0.3×	409 1.4×	92 0.5×	122	5.7k
Lyle D. Burgoon United States	32	926 1.2×	45 0.1×	203 0.7×	130 0.5×	73 0.4×	84	2.8k
William A. Ricke United States	36	1.4k 1.8×	146 0.4×	89 0.3×	438 1.5×	118 0.6×	119	4.7k
Antonio Rodríguez‐Ariza Spain	33	1.2k 1.6×	162 0.4×	101 0.3×	344 1.2×	93 0.5×	86	3.1k
Nisha S. Sipes United States	30	1.2k 1.5×	81 0.2×	162 0.6×	116 0.4×	221 1.1×	48	3.8k
Tim Zacharewski United States	29	811 1.0×	53 0.1×	122 0.4×	136 0.5×	45 0.2×	70	3.4k
Zhenzhen Pan China	26	673 0.9×	47 0.1×	121 0.4×	157 0.5×	336 1.7×	72	2.3k
Robert C. Sills United States	30	1.1k 1.4×	24 0.1×	81 0.3×	458 1.6×	99 0.5×	137	2.8k
Laura Gribaldo Italy	31	835 1.1×	27 0.1×	68 0.2×	229 0.8×	314 1.6×	107	2.7k
Zhihui Zhang China	31	1.6k 2.0×	27 0.1×	147 0.5×	349 1.2×	85 0.4×	186	3.6k

Countries citing papers authored by Brian Middleton

Since Specialization

Citations

This map shows the geographic impact of Brian Middleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Middleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Middleton more than expected).

Fields of papers citing papers by Brian Middleton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Middleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Middleton. The network helps show where Brian Middleton may publish in the future.

Co-authorship network of co-authors of Brian Middleton

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Middleton. A scholar is included among the top collaborators of Brian Middleton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Middleton. Brian Middleton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Middleton, Brian, Marcel Nijland, Lydia Visser, et al.. (2022). Anti-CD37 radioimmunotherapy with 177Lu-NNV003 synergizes with the PARP inhibitor olaparib in treatment of non-Hodgkin’s lymphoma in vitro. PLoS ONE. 17(4). e0267543–e0267543. 3 indexed citations

Patzke, Sebastian, et al.. (2020). ¹⁷⁷Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma. Journal of Nuclear Medicine. 61(10). 1468–1475. 5 indexed citations

Proctor, William R., Alison J. Foster, Jennifer Vogt, et al.. (2017). Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Archives of Toxicology. 91(8). 2849–2863. 219 indexed citations

Abbott, W. Mark, et al.. (2015). Optimisation of a simple method to transiently transfect a CHO cell line in high-throughput and at large scale. Protein Expression and Purification. 116. 113–119. 23 indexed citations

Winiwarter, Susanne, et al.. (2015). Time dependent analysis of assay comparability: a novel approach to understand intra- and inter-site variability over time. Journal of Computer-Aided Molecular Design. 29(9). 795–807. 15 indexed citations

Sohlenius-Sternbeck, Anna-Karin, Chris Jones, Douglas Ferguson, et al.. (2012). Practical use of the regression offset approach for the prediction ofin vivointrinsic clearance from hepatocytes. Xenobiotica. 42(9). 841–853. 75 indexed citations

Thompson, Richard A., Emre M. Isin, Yan Li, et al.. (2012). In Vitro Approach to Assess the Potential for Risk of Idiosyncratic Adverse Reactions Caused by Candidate Drugs. Chemical Research in Toxicology. 25(8). 1616–1632. 153 indexed citations

Martin, Scott, et al.. (2010). High‐throughput metabolic stability studies in drug discovery by orthogonal acceleration time‐of‐flight (OATOF) with analogue‐to‐digital signal capture (ADC). Rapid Communications in Mass Spectrometry. 24(12). 1730–1736. 11 indexed citations

Fridén, Markus, et al.. (2009). Development of a High-Throughput Brain Slice Method for Studying Drug Distribution in the Central Nervous System. Drug Metabolism and Disposition. 37(6). 1226–1233. 87 indexed citations

10.

Assem, E. S. K., et al.. (2009). Effects of a selection of histone deacetylase inhibitors on antigen- and agonist(s)-induced tracheal smooth muscle contraction. Inflammation Research. 58(S1). 22–23. 1 indexed citations

11.

Middleton, Brian, et al.. (2008). Effects of a selection of histone deacetylase inhibitors on mast cell activation and airway and colonic smooth muscle contraction. International Immunopharmacology. 8(13-14). 1793–1801. 28 indexed citations

12.

Middleton, Brian, et al.. (2008). Sensitivity of disease parameters to flexible budesonide/formoterol treatment in an allergic rat model. Pulmonary Pharmacology & Therapeutics. 22(1). 20–26. 3 indexed citations

13.

Middleton, Brian, et al.. (2007). An Optimized Automated Assay for Determination of Metabolic Stability Using Hepatocytes: Assay Validation, Variance Component Analysis, and In Vivo Relevance. Assay and Drug Development Technologies. 5(3). 403–416. 17 indexed citations

14.

Checkley, D., Jean Tessier, Stephen R. Wedge, et al.. (2003). Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts. Magnetic Resonance Imaging. 21(5). 475–482. 48 indexed citations

15.

Hughes, Denis, et al.. (2002). Regional water resource assessments in the SADC region. IAHS-AISH publication. 11–18. 4 indexed citations

16.

Middleton, Brian, et al.. (2002). Identification of in Vitro Folding Conditions for Procathepsin S and Cathepsin S Using Fractional Factorial Screens. Protein Expression and Purification. 24(2). 242–254. 42 indexed citations

17.

Tonge, Robert, Joanne Shaw, Brian Middleton, et al.. (2001). Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. PROTEOMICS. 1(3). 377–396. 706 indexed citations breakdown →

18.

Jones, H. B., et al.. (1994). Pathological and morphometric assessment of testicular parameters in patients with metastatic prostate cancer following treatment with either the antiandrogen Casodex (ZM176,334) or bilateral orchidectomy. Urological Research. 22(3). 191–195. 9 indexed citations

19.

Middleton, Brian. (1989). Surface water resources of South Africa. 1989. 331–332. 217 indexed citations

20.

Middleton, Brian, et al.. (1987). The assessment of micronucleated polychromatic erythrocytes in rat bone marrow Technical and statistical considerations. Mutation Research/Environmental Mutagenesis and Related Subjects. 182(6). 323–332. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact